Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2024 Apr 9

PMID 38592014

Authors

Francisco Navas

Ana Chocarro-Calvo

Patricia Iglesias-Hernandez

Paloma Fernandez-Garcia

Victoria Morales

Jose Manuel Garcia-Martinez

Raul Sanz

Antonio De la Vieja

Custodia Garcia-Jimenez

Rafael A Garcia-Munoz

Affiliations

Soon will be listed here.

Abstract

We report two novel prodrug Pt(IV) complexes with bis-organosilane ligands in axial positions: -dichloro(diamine)--[3-(triethoxysilyl)propylcarbamate]platinum(IV) (Pt(IV)-biSi-1) and -dichloro(diisopropylamine)--[3-(triethoxysilyl) propyl carbamate]platinum(IV) (Pt(IV)-biSi-2). Pt(IV)-biSi-2 demonstrated enhanced cytotoxicity against colon cancer cells (HCT 116 and HT-29) compared with cisplatin and Pt(IV)-biSi-1. Notably, Pt(IV)-biSi-2 exhibited higher cytotoxicity toward cancer cells and lower toxicity on nontumorigenic intestinal cells (HIEC6). In preclinical mouse models of colorectal cancer, Pt(IV)-biSi-2 outperformed cisplatin in reducing tumor growth at lower concentrations, with reduced side effects. Mechanistically, Pt(IV)-biSi-2 induced permanent DNA damage independent of p53 levels. DNA damage such as double-strand breaks marked by histone gH2Ax was permanent after treatment with Pt(IV)-biSi-2, in contrast to cisplatin's transient effects. Pt(IV)-biSi-2's faster reduction to Pt(II) species upon exposure to biological reductants supports its superior biological response. These findings unveil a novel strategy for designing Pt(IV) anticancer prodrugs with enhanced activity and specificity, offering therapeutic opportunities beyond conventional Pt drugs.

References

Zhong Y, Jia C, Zhang X, Liao X, Yang B, Cong Y . Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes. Eur J Med Chem. 2020; 194:112229. DOI: 10.1016/j.ejmech.2020.112229. View

Martinez-Erro S, Navas F, Romani-Cubells E, Fernandez-Garcia P, Morales V, Sanz R . Kidney-Protector Lipidic Cilastatin Derivatives as Structure-Directing Agents for the Synthesis of Mesoporous Silica Nanoparticles for Drug Delivery. Int J Mol Sci. 2021; 22(15). PMC: 8348040. DOI: 10.3390/ijms22157968. View

Tchounwou P, Dasari S, Noubissi F, Ray P, Kumar S . Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol. 2021; 13:303-328. PMC: 7987268. DOI: 10.2147/JEP.S267383. View

Hall M, Dillon C, Zhang M, Beale P, Cai Z, Lai B . The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. J Biol Inorg Chem. 2003; 8(7):726-32. DOI: 10.1007/s00775-003-0471-6. View

Lemma K, Shi T, Elding L . Kinetics and mechanism for reduction of the anticancer prodrug trans,trans,trans-[PtCl2(OH)2(c-C6H11NH2)(NH3)] (JM335) by thiols. Inorg Chem. 2003; 39(8):1728-34. DOI: 10.1021/ic991351l. View

Wheate N, Walker S, Craig G, Oun R . The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010; 39(35):8113-27. DOI: 10.1039/c0dt00292e. View

Wesolowska O, Michalak K, Blaszczyk M, Molnar J, Sroda-Pomianek K . Organosilicon Compounds, SILA-409 and SILA-421, as Doxorubicin Resistance-Reversing Agents in Human Colon Cancer Cells. Molecules. 2020; 25(7). PMC: 7181076. DOI: 10.3390/molecules25071654. View

Pillozzi S, DAmico M, Bartoli G, Gasparoli L, Petroni G, Crociani O . The combined activation of K3.1 and inhibition of K11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. Br J Cancer. 2017; 118(2):200-212. PMC: 5785745. DOI: 10.1038/bjc.2017.392. View

Johnstone T, Suntharalingam K, Lippard S . Third row transition metals for the treatment of cancer. Philos Trans A Math Phys Eng Sci. 2015; 373(2037). PMC: 4342973. DOI: 10.1098/rsta.2014.0185. View

10.

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

11.

Ronconi L, Sadler P . Applications of heteronuclear NMR spectroscopy in biological and medicinal inorganic chemistry. Coord Chem Rev. 2020; 252(21):2239-2277. PMC: 7094630. DOI: 10.1016/j.ccr.2008.01.016. View

12.

Morales V, McConnell J, Perez-Garnes M, Almendro N, Sanz R, Garcia-Munoz R . L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease. J Mater Chem B. 2021; 9(20):4178-4189. DOI: 10.1039/d1tb00481f. View

13.

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

14.

Riddell I . Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions. Met Ions Life Sci. 2018; 18. DOI: 10.1515/9783110470734-007. View

15.

Volckova E, Weaver E, Bose R . Insight into the reactive form of the anticancer agent iproplatin. Eur J Med Chem. 2007; 43(5):1081-4. DOI: 10.1016/j.ejmech.2007.06.019. View

16.

Babu T, Sarkar A, Karmakar S, Schmidt C, Gibson D . Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules. Inorg Chem. 2020; 59(7):5182-5193. DOI: 10.1021/acs.inorgchem.0c00445. View

17.

Li H, Wang Z, Zhang H, Pan Z . Nanoporous PLA/(Chitosan Nanoparticle) Composite Fibrous Membranes with Excellent Air Filtration and Antibacterial Performance. Polymers (Basel). 2019; 10(10). PMC: 6404119. DOI: 10.3390/polym10101085. View

18.

Kennedy L, Sandhu J, Harper M, Cuperlovic-Culf M . Role of Glutathione in Cancer: From Mechanisms to Therapies. Biomolecules. 2020; 10(10). PMC: 7600400. DOI: 10.3390/biom10101429. View

19.

Lemma K, Berglund J, Farrell N, Elding L . Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione. J Biol Inorg Chem. 2000; 5(3):300-6. DOI: 10.1007/pl00010658. View

20.

Amaral J, Xavier J, Steer C, Rodrigues C . Targeting the p53 pathway of apoptosis. Curr Pharm Des. 2010; 16(22):2493-503. DOI: 10.2174/138161210791959818. View